This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of amikacin injection: A Synthesis of Findings from 11 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of amikacin injection: A Synthesis of Findings from 11 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to Dataset
Please check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Amiodarone is an effective drug for maintaining sinus rhythm in atrial fibrillation, but it is associated with potentially serious toxic effects. 9 Dronedarone, a new antiarrhythmic agent pharmacologically related to amiodarone, was developed to reduce the risk of side effects. 9 Amiodarone is predominantly a Vaughan Williams Class III agent, but also possesses electrophysiological characteristics of the other three Vaughan Williams classes (Class I and IV and minor Class II effects). 4 Amiodarone’s primary mechanism is to prolong the cardiac action potential and repolarization time leading to an increased refractory period and reduced membrane excitability. 4 The efficacy and tolerability of intravenous (IV) amiodarone for acute treatment of recurrent and refractory ventricular tachycardia and ventricular fibrillation has been demonstrated in clinical trials. 4 The ARREST trial, a randomized trial comparing IV amiodarone to placebo, found a significant improvement in the proportion of patients surviving to the emergency department following out-of-hospital cardiac arrest in amiodarone-treated patients. 4 Intravenous amiodarone is an effective anti-arrhythmic agent for the acute treatment of life-threatening ventricular arrhythmias and represents an important treatment option for emergency anti-arrhythmic therapy for patients suffering from cardiac arrest. 4 Unlike other antiarrhythmic class I drugs, amiodarone showed in preliminary studies, benefits also in patients with left ventricular dysfunction. 3 These positive results have induced the development of large randomised controlled studies: their results are reviewed and the controversial points are discussed. 3 In a meta-analysis of randomised controlled trials the use of amiodarone in heart failure was associated with an approximate 20 to 25% reduction in deaths. 3 However, amiodarone was also associated with a 120 to 124% increase in side effects. 3 Lidocaine is still considered the drug of choice in the treatment of life-threatening ventricular arrhythmias in the setting of acute myocardial infarction (A.M.I.). 2 This is mainly due to its proved efficacy and high therapeutic index. 2 Lidocaine has well-defined electrophysiologic properties (class 1 B) and does not seem to be effective in all of these patients, so we compared its antiarrhythmic efficacy with the one of amiodarone (A), an antiarrhythmic agent provided of electrophysiologic properties quite different from L (class 4) and usually well tolerated. 2 Amiodarone is an effective antiarrhythmic drug, but it has serious side effects and conducted trials did not support its prophylactic use in survivors of acute myocardial infarction. 7 It is possible that the prophylactic use of the drug has not been tested effectively. 7 To optimize therapy outcome, markers of drug efficacy might be developed to identify patients who, although at arrhythmic risk, would not benefit from amiodarone treatment. 7 We investigated descriptors of QT/RR relationship for their potential value in predicting inefficient amiodarone treatment. 7 Amiodarone is very effective against a variety of dysrhythmias but has poor pharmacodynamic properties and many undesired side-effects. 5 Its short- and rapid-acting derivative E 047/1 may circumvent some of these drawbacks. 5 It is easier to titrate while retaining the high efficacy of amiodarone and may have acceptable influences on haemodynamics and cardiac conduction in patients who develop serious, destabilizing ventricular tachydysrhythmias after cardiac surgery. 5 Amiodarone is an excellent antiarrhythmic medication; however, it has numerous systemic and ocular adverse effects. 10

Benefits and Risks

Benefits Summary

Amiodarone is an effective drug for treating atrial fibrillation and ventricular arrhythmias. 9 4 A meta-analysis showed that it reduced mortality in heart failure patients by approximately 20 to 25%. 3 Intravenous administration of amiodarone has been shown to significantly improve the survival rate of patients following out-of-hospital cardiac arrest. 4 Dronedarone has a lower risk of side effects compared to amiodarone. 9

Risks Summary

Amiodarone can cause serious side effects, including thyroid dysfunction, pulmonary toxicity, and hepatotoxicity. 3 10 It can also cause eye side effects. 10 Although dronedarone has a lower risk of side effects than amiodarone, caution is still needed. 9

Comparison of Studies

Commonalities of Studies

All these studies demonstrate that amiodarone is effective in treating atrial fibrillation and ventricular arrhythmias. 9 4 3 They also share that amiodarone can cause side effects. 3 10

Differences of Studies

There are differences in the types and severity of amiodarone side effects, the duration of the effects, and so on. 9 4 3 11 There are also differences in the patients studied and the design of the studies. 9 4 3 11 2 7 5 1 6 8

Consistency and Contradictions in the Findings

While these studies show that amiodarone is effective in treating atrial fibrillation and ventricular arrhythmias, the findings on side effects vary depending on the study. 3 10 Further research on amiodarone side effects is needed. 10

Points to Note When Applying the Results to Real Life

Amiodarone can cause serious side effects, so it is important to take it as directed by your doctor. 3 10 Regular medical checkups are needed to detect amiodarone side effects early. 3 10

Limitations of Current Research

These studies have a limited number of participants, so it is unclear whether the results can be generalized. 9 4 3 11 Also, the differences in the study designs and evaluation methods make it difficult to directly compare the results. 9 4 3 11 2 7 5 1 6 8

Future Research Directions

Larger-scale studies on the side effects of amiodarone are needed. 3 10 Development of new therapies to reduce the side effects of amiodarone is also expected. 3 10

Conclusion

Amiodarone is an effective drug for treating atrial fibrillation and ventricular arrhythmias, but it can cause serious side effects. 3 10 When considering the use of amiodarone, it is important to discuss the risks and benefits with your doctor and make an informed decision. 3 10


Literature analysis of 11 papers
Positive Content
8
Neutral Content
0
Negative Content
3
Article Type
8
3
2
1
11

Language : English


Language : Italian


Language : English


Language : English


Language : English


Language : English


Language : English


Language : Chinese


Language : English


Language : English


Language : English


This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.